(Reuters) -Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a ...

The Bengaluru-based pharma company is run by Ajay Bhardwaj, a former Biocon executive, who is the founder, CEO and Managing Director at Anthem Biosciences. The company was incorporated in 2006.